Hunan Warrant Pharmaceutical Co.Ltd(688799)
Opinions of independent directors on matters related to the third meeting of the third board of directors
Prior approval opinion
In accordance with the relevant provisions of the company law of the people’s Republic of China, the Listing Rules of the science and Innovation Board of Shanghai Stock Exchange, the rules of independent directors of listed companies, the guidelines for the performance of duties of independent directors of listed companies and the articles of association of Hunan Warrant Pharmaceutical Co.Ltd(688799) (hereinafter referred to as the “company”), we, as independent directors of Hunan Warrant Pharmaceutical Co.Ltd(688799) (hereinafter referred to as the “company”), in a serious and responsible manner, based on an independent, prudent and objective position, On the basis of carefully reading the relevant meeting materials of the third meeting of the third session of the board of directors and listening to the reports of relevant personnel, after discussion, the following prior approval opinions are issued on the matters involved in the relevant proposals considered by the board of directors: I. prior approval opinions on the proposal on the confirmation of related party transactions of the company in 2021 and the prediction of related party transactions in 2022
We believe that the daily related party transactions of the company in 2021 and the related party transactions in 2022 are expected to be conducted based on the market-oriented principle, and the price is fair and reasonable. There is no damage to the interests of the company and minority shareholders, which will not affect the independence of the company and is in line with the interests of the company and all shareholders. In conclusion, we agree to submit the related party transaction to the third meeting of the third board of directors of the company for deliberation.
(no text below)
Independent directors: Peng Tong, Wu Chun, Kang Cailian March 24, 2022
